MOLTENI, ELISABETTA
MOLTENI, ELISABETTA
DMED - DIPARTIMENTO DI MEDICINA
Cellular residual disease (CRD) in early breast cancer –Expanding the concept of minimal residual disease monitoring?
2023-01-01 Serafini, Mara S.; Molteni, Elisabetta; Nicolò, Eleonora; Gerratana, Lorenzo; Reduzzi, Carolina; Cristofanilli, Massimo
Dihydrotanshinone I exhibits antitumor effects via β-catenin downregulation in papillary thyroid cancer cell lines
2024-01-01 Molteni, E.; Baldan, F.; Damante, G.; Allegri, L.
GSK2801 Reverses Paclitaxel Resistance in Anaplastic Thyroid Cancer Cell Lines through MYCN Downregulation
2023-01-01 Molteni, E.; Baldan, F.; Damante, G.; Allegri, L.
Is ctDNA ready to outpace imaging in monitoring early and advanced breast cancer?
2024-01-01 Foffano, Lorenzo; Vida, Riccardo; Piacentini, Alberto; Molteni, Elisabetta; Cucciniello, Linda; Da Ros, Lucia; Buriolla, Silvia; Cereser, Lorenzo; Roncato, Rossana; Gerratana, Lorenzo; Puglisi, Fabio
Longitudinal profiling of hormone receptor positive, HER2 negative metastatic breast cancer through droplet digital PCR-based circulating tumor DNA fragmentomics
2025-01-01 Foffano, L.; Franzoni, A.; Molteni, E.; Giudici, F.; Dri, A.; Basile, D.; Cucciniello, L.; Buriolla, S.; Noto, C.; Russo, S.; Nascimbeni, E.; Bolzonello, S.; Pasto, B.; Rossa, S. D.; Allegri, L.; Bonotto, M.; Minisini, A. M.; Belletti, B.; Damante, G.; Gerratana, L.; Puglisi, F.
Real-time assessment of HER2 status in circulating tumor cells of breast cancer patients: Methods of detection and clinical implications
2023-01-01 Nicolò, Eleonora; Serena Serafini, Mara; Munoz-Arcos, Laura; Pontolillo, Letizia; Molteni, Elisabetta; Bayou, Nadia; Andreopoulou, Eleni; Curigliano, Giuseppe; Reduzzi, Carolina; Cristofanilli, Massimo
Role of m6A RNA Methylation in Thyroid Cancer Cell Lines
2022-01-01 Allegri, L.; Baldan, F.; Molteni, E.; Mio, C.; Damante, G.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Cellular residual disease (CRD) in early breast cancer –Expanding the concept of minimal residual disease monitoring? | 1-gen-2023 | Serafini, Mara S.; Molteni, Elisabetta; Nicolò, Eleonora; Gerratana, Lorenzo; Reduzzi, Carolina; Cristofanilli, Massimo | |
| Dihydrotanshinone I exhibits antitumor effects via β-catenin downregulation in papillary thyroid cancer cell lines | 1-gen-2024 | Molteni, E.; Baldan, F.; Damante, G.; Allegri, L. | |
| GSK2801 Reverses Paclitaxel Resistance in Anaplastic Thyroid Cancer Cell Lines through MYCN Downregulation | 1-gen-2023 | Molteni, E.; Baldan, F.; Damante, G.; Allegri, L. | |
| Is ctDNA ready to outpace imaging in monitoring early and advanced breast cancer? | 1-gen-2024 | Foffano, Lorenzo; Vida, Riccardo; Piacentini, Alberto; Molteni, Elisabetta; Cucciniello, Linda; Da Ros, Lucia; Buriolla, Silvia; Cereser, Lorenzo; Roncato, Rossana; Gerratana, Lorenzo; Puglisi, Fabio | |
| Longitudinal profiling of hormone receptor positive, HER2 negative metastatic breast cancer through droplet digital PCR-based circulating tumor DNA fragmentomics | 1-gen-2025 | Foffano, L.; Franzoni, A.; Molteni, E.; Giudici, F.; Dri, A.; Basile, D.; Cucciniello, L.; Buriolla, S.; Noto, C.; Russo, S.; Nascimbeni, E.; Bolzonello, S.; Pasto, B.; Rossa, S. D.; Allegri, L.; Bonotto, M.; Minisini, A. M.; Belletti, B.; Damante, G.; Gerratana, L.; Puglisi, F. | |
| Real-time assessment of HER2 status in circulating tumor cells of breast cancer patients: Methods of detection and clinical implications | 1-gen-2023 | Nicolò, Eleonora; Serena Serafini, Mara; Munoz-Arcos, Laura; Pontolillo, Letizia; Molteni, Elisabetta; Bayou, Nadia; Andreopoulou, Eleni; Curigliano, Giuseppe; Reduzzi, Carolina; Cristofanilli, Massimo | |
| Role of m6A RNA Methylation in Thyroid Cancer Cell Lines | 1-gen-2022 | Allegri, L.; Baldan, F.; Molteni, E.; Mio, C.; Damante, G. |